"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 4 | 4 | 8 |
| 2004 | 2 | 4 | 6 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 2 | 3 |
| 2009 | 4 | 2 | 6 |
| 2010 | 2 | 3 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 2 | 2 | 4 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 2 | 4 |
| 2016 | 4 | 2 | 6 |
| 2017 | 2 | 2 | 4 |
| 2018 | 3 | 0 | 3 |
| 2019 | 5 | 4 | 9 |
| 2020 | 4 | 4 | 8 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 5 | 5 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Idiopathic inflammatory myopathies related lung disease in adults. Lancet Respir Med. 2025 Mar; 13(3):272-288.
-
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma. 2023 05; 64(5):1026-1034.
-
Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients. J Am Soc Nephrol. 2023 01 01; 34(1):160-174.
-
Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide. Rheumatology (Oxford). 2020 Sep 01; 59(9):2264-2271.
-
Should Pre-Transplant Hemoglobin A1c Be Used to Predict Post-Transplant Compliance in End-Stage Renal Disease Patients Undergoing Kidney Transplantation? Ann Transplant. 2020 Jun 26; 25:e924061.
-
Phase I trial of donor-derived modified immune cell infusion in kidney transplantation. J Clin Invest. 2020 05 01; 130(5):2364-2376.
-
Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019 10 29; 93(18):e1732-e1741.
-
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA. 2019 01 15; 321(2):165-174.
-
Targeting mTOR Signaling Can Prevent the Progression of FSGS. J Am Soc Nephrol. 2017 Jul; 28(7):2144-2157.
-
Immunogenetics of cutaneous lupus erythematosus. Curr Opin Pediatr. 2016 08; 28(4):470-5.